In the present study, we report a novel triazole derivative (4-[(1E)-2-(2-phenylindol-3-yl)-1-azavinyl]-1,2,4-triazole (Figure 1A) named MortaparibPlus that was selected as a potential mortalin-p53 disruptor in the same screening using human osteosarcoma (U2OS) and Luminal-A breast-cancer (MCF-7) cells, both possessing wild-type p53 protein. This evidence concerns the gene HSPA9 and breast carcinoma.